The validity, responsiveness, and score interpretation of the PROMISnq Physical Function – Multiple Sclerosis 15a short form in multiple sclerosis-Reference-Cited by-同舟云学术

The validity, responsiveness, and score interpretation of the PROMISnq Physical Function – Multiple Sclerosis 15a short form in multiple sclerosis

Published:2022-06 Issue: Volume:62 Page:103753
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Kamudoni Paul,Amtmann Dagmar,Johns Jeffrey,Cook Karon F.,Salem Rana,Salek Sam,Raab Jana,Middleton Rod,Repovic Pavle,Alschuler Kevin N.,von Geldern Gloria,Wundes Annette,Barrett Amy,Olayinka-Amao Oyebimpe,Henke Christian

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference59 articles.

1. Amtmann, D, Bamer, AM, Kim, J, Chung, H, Salem, R, 2018. People with multiple sclerosis report significantly worse symptoms and health related quality of life than the US general population as measured by PROMIS and NeuroQoL outcome measures. Disabil Health J 11(1), 99-107.

2. European Medicines Agency, 2015. Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis.

3. Cleanthous, S, Cano, S, Kinter, E, et al., 2017. Measuring the impact of multiple sclerosis: Enhancing the measurement performance of the Multiple Sclerosis Impact Scale (MSIS-29) using Rasch Measurement Theory (RMT). Mult Scler J Exp Transl Clin 3(3).

4. Cella, D, Riley, W, Stone, A, et al., 2010. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol 63(11), 1179-1194.

5. Confavreux, C, Vukusic, S, 2006. Natural history of multiple sclerosis: a unifying concept. Brain 129(Pt 3), 606-616.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy;Frontiers in Neurology;2024-04-04

2. Understanding the Symptoms and Impacts Experienced by People with Relapsing–Remitting MS: A Qualitative Investigation Using Semi-Structured Interviews;Neurology and Therapy;2024-02-12

3. Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis;Advances in Therapy;2023-09-30